



AMENDMENTS TO THE CLAIMS


Claim 1 (currently amended): A quinazoline derivative of the Formula I





wherein Q^1 is a quinazoline-like ring such as a group of the formula Ia, Ib, Ic or Id



Ia



Ib



wherein :


~~Y¹ together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S provided that the group of formula Ic so formed is not a purine ring;~~

~~Y² together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;~~

m is 0, 1, 2, 3 or 4;

each R^1 group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl,


(1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein X^1 is a direct bond or is selected from O, S, SO, SO₂, N(R⁴), CO, CH(OR⁴), CON(R⁴), N(R⁴)CO, SO₂N(R⁴), N(R⁴)SO₂, OC(R⁴)₂, SC(R⁴)₂ and N(R⁴)C(R⁴)₂, wherein R⁴ is hydrogen or (1-6C)alkyl, and Q³ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocycl or heterocycl-(1-6C)alkyl, or (R¹)_m is (1-3C)alkylenedioxy,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO₂, N(R⁵), CO, CH(OR⁵), CON(R⁵), N(R⁵)CO, SO₂N(R⁵), N(R⁵)SO₂, CH=CH and C≡C wherein R⁵ is hydrogen or (1-6C)alkyl,


and wherein any CH₂=CH- or HC≡C- group within a R¹ substituent optionally bears at the terminal CH₂= or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :



wherein X^2 is a direct bond or is selected from CO and N(R⁶)CO, wherein R⁶ is hydrogen or (1-6C)alkyl, and Q⁴ is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocycl or heterocycl-(1-6C)alkyl,


and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more halogeno substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio,

(1-6C)alkylsulphanyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :




wherein X^3 is a direct bond or is selected from O, S, SO, SO₂, N(R⁷), CO, CH(OR⁷), CON(R⁷), N(R⁷)CO, SO₂N(R⁷), N(R⁷)SO₂, C(R⁷)₂O, C(R⁷)₂S and N(R⁷)C(R⁷)₂, wherein R⁷ is hydrogen or (1-6C)alkyl, and Q⁵ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocycl or heterocycl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocycl group within a substituent on R¹ optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphanyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein X^4 is a direct bond or is selected from O and N(R⁹), wherein R⁹ is hydrogen or (1-6C)alkyl, and R⁸ is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl, or from a group of the formula :



wherein X^5 is a direct bond or is selected from O and N(R¹⁰), wherein R¹⁰ is hydrogen or (1-6C)alkyl, and Q⁶ is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocycl or

heterocyclyl-(1-6C)alkyl, and any Q⁶ group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 oxo or thioxo substituents;

R² is hydrogen or (1-6C)alkyl and R³ is hydrogen or (1-6C)alkyl, or R² and R³ together form a CH₂, (CH₂)₂ or (CH₂)₃ group;

Z is O, S, N(C≡N) or N(R¹¹), wherein R¹¹ is hydrogen or (1-6C)alkyl; and

~~Q² is aryl, aryl-(1-3C)alkyl[,] or aryl-(3-7C)cycloalkyl, heteroaryl, heteroaryl-(1-3C)alkyl or heteroaryl-(3-7C)cycloalkyl~~ wherein each aryl group is phenyl or naphthyl and ~~each heteroaryl group is a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic heteroaryl ring containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur~~, and

Q² is optionally substituted with 1, 2, 3 or 4 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphanyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :


- X⁶ - R¹²

wherein X⁶ is a direct bond or is selected from O and N(R¹³), wherein R¹³ is hydrogen or (1-6C)alkyl, and R¹² is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :

- X⁷ - Q⁷

wherein X^7 is a direct bond or is selected from O, S, SO, SO₂, N(R¹⁴), CO, CH(OR¹⁴), CON(R¹⁴), N(R¹⁴)CO, SO₂N(R¹⁴), N(R¹⁴)SO₂, C(R¹⁴)₂O, C(R¹⁴)₂S and C(R¹⁴)₂N(R¹⁴), wherein each R¹⁴ is hydrogen or (1-6C)alkyl, and Q⁷ is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or Q² is optionally substituted with a (1-3C)alkylenedioxy group,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on Q² optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein X⁸ is a direct bond or is selected from O and N(R¹⁶), wherein R¹⁶ is hydrogen or (1-6C)alkyl, and R¹⁵ is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on Q² optionally bears 1 or 2 oxo or thioxo substituents;
or a pharmaceutically-acceptable salt thereof;
provided that the compounds :-

1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea[[,]] and
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea[[,]]
~~1-phenyl-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea,~~
~~1-(2-chlorophenyl)-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea,~~
~~1-(3-chlorophenyl)-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea,~~

~~1-(4-chlorophenyl)-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea,~~

~~1-(2-fluorophenyl)-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea,~~

~~1-benzyl-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea and~~

~~1-(3-phenylpropyl)-3-(pyrazolo[3,4-d]pyrimidin-4-yl)urea~~ are excluded.

Claims 2-5 (canceled).

Claim 6 (currently amended): A quinazoline derivative of the Formula **I H** according to claim 1 2 wherein :

m is 1 and the R¹ group is located at the 6- or 7-position and is selected from methoxy, benzyloxy, cyclopropylmethoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminoproxy, 3-diethylaminoproxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, N-methylpyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 2-(N-methylpyrrolidin-2-yl)ethoxy, 3-pyrrolidin-2-ylpropoxy, 3-(N-methylpyrrolidin-2-yl)propoxy, 2-(2-oxoimidazolidin-1-yl)ethoxy, 2-morpholinoethoxy, 3-morpholinoproxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-(4-aminomethylpiperidin-1-yl)propoxy, 3-(4-tert-butoxycarbonylaminopiperidin-1-yl)propoxy, 3-(4-carbamoylpiperidin-1-yl)propoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-1-yloxy, 2-(2-morpholinoethoxy)ethoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy, 3-[N-(2-methoxyethyl)-N-methylamino]propoxy, 2-(2-methoxyethoxy)ethoxy, 3-methylamino-1-propynyl,

3-dimethylamino-1-propynyl, 3-diethylamino-1-propynyl, 6-methylamino-1-hexynyl, 6-dimethylamino-1-hexynyl, 3-(pyrrolidin-1-yl)-1-propynyl, 3-(piperidino)-1-propynyl, 3-(morpholino)-1-propynyl, 3-(4-methylpiperazin-1-yl)-1-propynyl, 6-(pyrrolidin-1-yl)-1-hexynyl, 6-(piperidino)-1-hexynyl, 6-(morpholino)-1-hexynyl, 6-(4-methylpiperazin-1-yl)-1-hexynyl, piperazin-1-yl, 4-methylpiperazin-1-yl, 3-imidazol-1-ylpropylamino, 3-pyrrolidin-1-ylpropylamino, 3-morpholinopropylamino, 3-piperidinopropylamino and 3-piperazin-1-ylpropylamino,

or m is 2 and the R¹ groups are located at the 6- and 7-positions, one R¹ group is located at the 6- or 7-position and is selected from the groups defined immediately hereinbefore and the other R¹ group is a methoxy group;

R² is hydrogen or methyl;

R³ is hydrogen;

Z is O, S, NH or N(Et); and

Q² is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy provided that at least one substituent is located at an ortho position; or a pharmaceutically-acceptable acid-addition salt thereof; and provided that 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea is excluded.

Claim 7 (currently amended): A quinazoline derivative of the Formula I H according to claim 1 2 wherein :

m is 1 and the R¹ group is located at the 7-position and is selected from 3-(1,2,3-triazol-1-yl)propoxy, 2-pyrid-4-yloxy, 2-pyrrolidin-1-yloxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinoproxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-pyrrolidin-1-ylbut-2-en-1-yloxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-1-yloxy, 3-methylsulphonylpropoxy and 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy;

or m is 2 and one R¹ group is located at the 7-position and is selected from the groups defined immediately hereinbefore and the other R¹ group is a 6-methoxy group;

R² is hydrogen or methyl;

R³ is hydrogen;

Z is O, S, NH or N(Et); and

Q² is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy provided that at least one substituent is located at an ortho position; or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 8 (currently amended): A quinazoline derivative of the Formula I H according to claim 1 2 wherein :

m is 1 and the R¹ group is located at the 7-position and is selected from 3-(1,2,3-triazol-1-yl)propoxy, 2-pyrid-4-yloxy, 3-pyrrolidin-1-ylpropoxy, 3-morpholinopropoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, N-methylpiperidin-4-ylmethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-1-yloxy, 3-methylsulphonylpropoxy and 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy;

or m is 2 and one R¹ group is located at the 7-position and is selected from the groups defined immediately hereinbefore and the other R¹ group is a 6-methoxy group;

R² is hydrogen or methyl;

R³ is hydrogen;

Z is O; and

Q² is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo and trifluoromethyl provided that at least one substituent is located at an ortho position; or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 9 (currently amended): A quinazoline derivative of the Formula I H according to claim 1 2 selected from:-

1-(2,6-dichlorophenyl)-3-[7-(3-morpholinopropoxy)quinazolin-4-yl]urea,
1-(2,6-dichlorophenyl)-3-{7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]quinazolin-4-yl}urea,
1-benzyl-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,
1-phenethyl-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,
1-(2,6-dichlorophenyl)-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,
1-(2,6-difluorophenyl)-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,
1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,
1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,
1-(2,6-difluorophenyl)-3-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]urea,
1-(2,6-difluorophenyl)-3-[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl]urea,
1-(2,6-dimethylphenyl)-3-[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl]urea,
1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(3-piperidinopropoxy)quinazolin-4-yl]urea,
1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea and
1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]guanidine;
or a pharmaceutically-acceptable acid-addition salt thereof.

Claims 10-13 (canceled).

Claim 14 (original): A pharmaceutical composition which comprises a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, according to claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

Claim 15 (canceled).

Claim 16 (currently amended): A method for the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal in need of such treatment which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, according to claim 1 ~~but without the proviso that the group of formula Ic so formed is not a purine ring and including the compounds:-~~

~~1-(6,7-dimethoxyquinolin-4-yl)-3-phenylurea,~~

~~1-[5-(4-methoxyphenoxy)quinolin-4-yl]-3-phenylurea,~~

~~1-[5-(4-methoxyphenoxy)quinolin-4-yl]-3-(3-bromophenyl)urea,~~

~~1-[5-(4-methoxyphenoxy)quinolin-4-yl]-3-(3-methoxyphenyl)urea.~~

~~1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,~~

~~1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,~~

~~1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,~~

~~1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,~~

~~1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,~~

~~1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and~~

~~1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea.~~